Merck MS Drug Fails to Meet Target of Late-Stage Trials
By David Sachs
Merck's multiple sclerosis drug evobrutinib didn't meet a key goal in late-stage trials.
The German pharmaceutical company's phase 3 clinical trials for the drug did not achieve their primary target of reducing annualized relapse rates in people with relapsing multiple sclerosis, it said late Tuesday. The drugmaker was aiming to match the rate of Aubagio, an oral drug for the disease owned by Sanofi.
"While we are very disappointed with the results, we continue to advance our strategy in healthcare with a focus on progressing our marketed portfolio and internal pipeline, complemented by external innovation, with the aim of bringing more medicines to patients, faster," said Danny Bar-Zohar, head of research and development at Merck.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
December 06, 2023 01:22 ET (06:22 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations